RxDoctor Payments Data

Brandy Mize, MD

Pulmonary Disease · Columbus, GANPI 1790148203

Payments from drug & device makers

$8,783in general payments, 2019–2025

Across 182 payments — averaging $48.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Medtronic$2K
  • GSK$838
  • AstraZeneca$462
  • Boehringer Ingelheim$334
  • Regeneron Healthcare Solutions, Inc.$326
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$2,28226%
  • Food & beverage$3,48440%
  • Education$3,01734%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,783 in reported general payments places this provider in the 65th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$73,073
Medicare patients
275
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter499$380,866
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$67,051
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$56,868
Dupixent PenDupilumab13$56,820
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr86$42,583
Spiriva RespimatTiotropium Bromide46$31,829
Incruse ElliptaUmeclidinium Bromide50$21,284
Albuterol Sulfate HfaAlbuterol Sulfate599$17,978
Combivent RespimatIpratropium/Albuterol Sulfate26$12,588
Varenicline Tartrate37$9,144
Fluticasone-SalmeterolFluticasone Propion/Salmeterol71$8,860
Breo ElliptaFluticasone/Vilanterol20$8,815
Ventolin HfaAlbuterol Sulfate111$7,616
Advair HfaFluticasone Propion/Salmeterol18$7,392
Wixela InhubFluticasone Propion/Salmeterol68$6,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$838$459,425680 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$334$101,285142 claims
AstraZenecaBreztri Aerosphere, Symbicort$462$73,06291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →